The humanoid robotics industry is running on two clocks. In Liuzhou, UBTECH has begun producing industrial humanoid robots at a rate of one every ten minutes1,7. In Seoul, a Hyundai executive concedes that Boston Dynamics, with cumulative losses approaching 1.7 trillion won, is unlikely to reach an IPO by 20272,4. ANALYSIS The gap between capacity buildout and commercial viability is now the defining tension in the sector, and the two announcements landing in the same week make it impossible to ignore.
Why it matters
Humanoid robots have attracted enormous capital and public fascination, but the industry's economics remain unproven. Boston Dynamics posted an operating loss of 528.4 billion won in 2025 alone. Hyundai aims to build manufacturing capacity for 30,000 Atlas units annually by 2028, yet the executive's own words were blunt: "It won't be easy. We need to see the conditions and circumstances". ◆ That a parent company executive would publicly temper expectations, even anonymously, suggests the internal timeline has slipped further than Hyundai's capacity targets imply. Meritz Securities analyst Kim Joon-sung has placed a more realistic IPO window around 2029 or 2030.
The big picture
UBTECH's Liuzhou plant, commissioned September 12, spans roughly 14,000 square meters and targets annual capacity exceeding 10,000 units. The facility produces Walker S series and Cruzr series platforms on flexible mixed-model lines built in collaboration with Siemens, incorporating digital twin technology and the Yanshee MOM manufacturing operations management system3. Workpieces ride self-docking rotating dollies with RFID-linked serial tracking, and automated torque stations drive more than 2,000 fasteners across roughly 50 specifications. Completed units pass through more than four hours of burn-in testing and an automotive-grade lighting tunnel for visual inspection.
The production news drove UBTECH's Hong Kong-listed shares up more than 3% in early trading on September 14, touching an intraday high of HK$80.4 with turnover of HK$125 million8. Meanwhile, across the broader Chinese humanoid sector, Unitree's average selling price has fallen 72% in two years, with consumer models now available in the $4,500 range6. Localization of core components exceeding 75% has driven that decline.
ANALYSIS Chinese manufacturers are competing on production scale and cost compression in a way that Boston Dynamics, still pre-revenue at meaningful volume, is not yet positioned to match.
Between the lines
AGIBOT co-founder Yao Maoqing offered a third data point at the Fortune Leaders Forum in Macau: "As models keep maturing, [embodied AI] will reach GPT-3.5. People differ somewhat on timing, but overall it's within the 3-to-5-year window"5. ◆ The analogy is telling. GPT-3.5 was the moment large language models crossed from research curiosity to mass adoption. Yao is framing humanoid robotics as pre-threshold, useful enough to deploy in controlled settings but not yet reliable enough for open-ended commercial purchasing at scale.
Industry observers echo that caution. Despite the price drops, analysts cited in Chinese tech media argue that operational reliability and AI "brain" technology, not price cuts, will be the key commercialization variables, with standardized commercial purchasing expected to gain momentum around 2028 to 2030. ◆ That timeline aligns more closely with the Meritz Securities estimate for a Boston Dynamics IPO than with UBTECH's factory-floor ambitions, suggesting the supply side is running well ahead of validated demand.
The UBTECH factory itself embodies this tension. As one analysis noted, "Building the plant is one thing; filling its order book is another. Automakers and logistics groups are already trialing the Walker S in their operations, but the leap from pilot programs to binding four-digit purchase commitments is far from assured". ◆ A 10,000-unit annual capacity line operating below utilization would convert fixed-cost leverage into a drag on margins.
What's next
Hyundai's 30,000-unit Atlas manufacturing target is set for 2028. UBTECH's Liuzhou plant is operational now. ◆ The next twelve months will test whether either company can convert installed capacity into sustained order flow. The scheduled 2028-to-2030 window that multiple analysts and industry insiders have converged on for meaningful commercial purchasing leaves a multi-year gap in which factories are built, losses accumulate, and the sector's credibility rests on pilot deployments rather than purchase orders. UBTECH delivered 1,079 full-size Walker S2 units last year. Whether that figure scales toward the plant's capacity will be the clearest early signal of whether humanoid manufacturing has outrun humanoid demand.